Corporation
Gilead Sciences Canada
- Meetings this Parliament
- 47
- With MPs
- 12
- Since Nov 2021
- 107
- Active registrations
- 1
Most recent reported meeting: Sep 22, 2026.
Lobbying by Gilead Sciences Canada: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Apr 2, 2026
Filed by Paul Petrelli, General Manager
Lobbyists
- Bobby Sutherland · Sr. Director, Government Affairs
- Paul Petrelli · General Manager
Institutions they may lobby: CUSMA Secretariat, Canadian Institutes of Health Research (CIHR), Correctional Service of Canada (CSC), Crown-Indigenous Relations and Northern Affairs Canada (CIRNAC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Immigration, Refugees and Citizenship Canada (IRCC), Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (9)Hide details
- Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
- Food and Drug regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
- Canada's Drug Agency (CDA) policies as it relates to health economics assessment and recommendations made on new medicines.
- Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
- Free Trade agreements as they relate to the biopharmaceutical industry
- Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
- Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
- Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
- Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Registration 959600-360912-19. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Paul Petrelli (50), Christophe Griolet (39), Scott Spencer (9), Melissa Koomey (9).
-
Reported by Paul Petrelli · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
-
Reported by Paul Petrelli · In-house (corporation)
- René Cormier · Senator, Senate of Canada
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
-
Reported by Paul Petrelli · In-house (corporation)
- Joan Kingston · Senator, Senate of Canada
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
-
Reported by Paul Petrelli · In-house (corporation)
- Kristopher Wells · Senator, Senate of Canada
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
-
Reported by Paul Petrelli · In-house (corporation)
- Ziad Aboultaif · Member of Parliament
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
-
Reported by Paul Petrelli · In-house (corporation)
- Steven Sternthal · Director General, Public Health Agency of Canada (PHAC)
Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19. Read more
-
Reported by Paul Petrelli · In-house (corporation)
- Paul Moen · Chief of Staff to the Minister, Innovation, Science and Economic Development Canada (ISED)
- Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19. Read more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
-
Reported by Paul Petrelli · In-house (corporation)
- Ian Foucher · Chief of Staff, Finance Canada (FIN)
- Scott Winter · Director General, International Trade Policy Division, Finance Canada (FIN)
- Matthew O'Connell · Deputy Director Financial Sector Policy, Finance Canada (FIN)
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution. Read more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
-
Reported by Paul Petrelli · In-house (corporation)
- Ali Ehsassi · Member of Parliament
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution. Read more
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
-
Reported by Paul Petrelli · In-house (corporation)
- David McFarlane · Director of Policy, Innovation, Science and Economic Development Canada (ISED)
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution. Read more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
-
Reported by Paul Petrelli · In-house (corporation)
- Shelby Kramp-Neuman · Member of Parliament
- Randy Hoback · Member of Parliament
- Holly Duggan · Director of Stakeholder Relations, House of Commons
- Darren Hall · Policy Advisor, House of Commons
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution. Read more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
-
Reported by Paul Petrelli · In-house (corporation)
- Wilder Walker-Stewart · Director of Policy, Public Services and Procurement Canada (PSPC)
- Yianni Papadatos · Director of Parliamentary Affairs, Public Services and Procurement Canada (PSPC)
- Kabisan Thanendran · Policy Advisor, Public Services and Procurement Canada (PSPC)
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
-
Reported by Paul Petrelli · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Ali Ehsassi · Member of Parliament
- Brandan Rowe · Chief of Staff, Privy Council Office (PCO)
- Rob Stewart · Deputy Minister of International Trade, Intergovernmental Affairs Secretariat (IGA)
and 2 moreShow fewer
- Martin Moen · Associate Assistant Deputy Minister, Intergovernmental Affairs Secretariat (IGA)
- Jason LaTorre · Director General, Intergovernmental Affairs Secretariat (IGA)
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution. Read more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
-
Reported by Paul Petrelli · In-house (corporation)
- Sandenga Yeba · Director of Policy and Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
- Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
- Bryn Savage · Policy Advisor, Health Canada (HC)
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution. Read more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
-
Reported by Paul Petrelli · In-house (corporation)
- Elliott Lockington · Chief of Staff, Finance Canada (FIN)
- Elizabeth Wong · Policy Advisor, Finance Canada (FIN)
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
-
Reported by Paul Petrelli · In-house (corporation)
- Sandenga Yeba · Director of Policy and Deputy Chief of Staff, Health Canada (HC)
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries. Read more
Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
-
Reported by Paul Petrelli · In-house (corporation)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
-
Reported by Paul Petrelli · In-house (corporation)
- Rodrigo Arancibia · Director General, Innovation, Science and Economic Development Canada (ISED)
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
-
Reported by Paul Petrelli · In-house (corporation)
- Yash Nanda · Senior Policy Advisor, Prime Minister's Office (PMO)
Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19. Read more
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
-
Reported by Paul Petrelli · In-house (corporation)
- Mona Nemer · Chief Science Advisor, Innovation, Science and Economic Development Canada (ISED)
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution. Read more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
-
Reported by Paul Petrelli · In-house (corporation)
- Sandenga Yeba · Director of Policy and Deputy Chief of Staff, Health Canada (HC)
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries. Read more
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
-
Reported by Paul Petrelli · In-house (corporation)
- Steven Sternthal · Director General, Public Health Agency of Canada (PHAC)
Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19. Read more
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
-
Reported by Paul Petrelli · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more
Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
-
Reported by Paul Petrelli · In-house (corporation)
- Fatima Asghar · Policy Advisor, Health Canada (HC)
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries. Read more
Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
-
Reported by Paul Petrelli · In-house (corporation)
- Katherine McAllister · Director of Parliamentary Affairs, House of Commons
Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19. Read more
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.